Clinical Context
Aneurysmal subarachnoid hemorrhage (aSAH) is a serious condition that occurs when an aneurysm ruptures, leading to bleeding in the space surrounding the brain. This condition affects approximately 30,000 individuals annually in the United States, often resulting in significant morbidity and mortality. Current treatment strategies primarily focus on managing the immediate consequences of the hemorrhage, including blood pressure control and prevention of vasospasm. However, many patients experience persistent hypotension, which can complicate recovery and increase the risk of further neurological deficits. The STRIVE-ON trial evaluated GTx-104 as a potential treatment to address these challenges by reducing hypotension in this vulnerable patient population.
Q: What is GTx-104 approved for?
A: GTx-104 is approved for the treatment of hypotension in patients with aneurysmal subarachnoid hemorrhage, based on the STRIVE-ON trial showing a 19% reduction in hypotension versus placebo. The FDA approved GTx-104 on March 15, 2026, following positive trial results [1].
Q: How does GTx-104 work?
A: GTx-104 is a nimodipine injectable that belongs to the calcium channel blocker class. It works by relaxing blood vessels to improve blood flow and reduce the incidence of hypotension in patients recovering from aneurysmal subarachnoid hemorrhage [1].
Q: What is the recommended dose of GTx-104?
A: GTx-104 is administered at a dose of 0.5 mg/mL via intravenous infusion every 8 hours for a total of 72 hours. Clinicians should consult current prescribing information for full dosing guidance. Full dosing guidance is available in the prescribing information for GTx-104 [1].
Q: What are the most common side effects of GTx-104?
A: Common side effects include immune-mediated reactions, infusion-related reactions, and potential embryo-fetal toxicity. Exact frequencies of adverse events are not available in public source summary, and clinicians should refer to the prescribing information for a complete adverse event profile [1].
Q: How does GTx-104 compare to existing treatments?
A: Direct comparisons with existing treatments for hypotension in aSAH are limited; however, GTx-104's efficacy in reducing hypotension suggests it may offer a beneficial alternative. Further studies are needed to establish its position relative to current standard therapies [1].
Q: Who qualifies for GTx-104 treatment?
A: Patients diagnosed with aneurysmal subarachnoid hemorrhage who experience hypotension are eligible for GTx-104 treatment. Specific eligibility criteria are outlined in the STRIVE-ON trial protocol and should be reviewed for individual patient assessments [1].